Singapore molecular diagnostics groups INEX Innovations Exchange and Nova Satra, a pioneer in healthcare analytics merge business unit to create INEX Innovate. The deal is valued at $72m. The combined company will be focused on addressing the unmet need for faster and more accurate diagnostics testing and precision health care for Asian women. The deal is backed by institutional investors including Genting, Enterprise Singapore, and SNS Holdings. “We are delighted to launch INEX INNOVATE and will continue to work to empower Asian women in the management of their own health through improved access to rapid, accurate diagnosis and technologies. This merger is a strategic step to expedite that ambition." Kane Black, INEX Innovate CEO.